Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 3Thoracic 2Sarcoma 2Plasma cell 2Lymphoid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Multiple Myeloma 111Neoplasms, Plasma Cell 50Lymphoma, Non-Hodgkin 39Lymphoma 35Hodgkin Disease 35Myelodysplastic Syndromes 32Leukemia, Lymphocytic, Chronic, B-Cell 32Leukemia 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Lymphoma, Follicular 29Lymphoma, Mantle-Cell 28Lymphoma, Large-Cell, Immunoblastic 28Burkitt Lymphoma 28Lymphoma, Large B-Cell, Diffuse 27Lymphoma, B-Cell, Marginal Zone 27Leukemia, Myeloid, Acute 23Myeloproliferative Disorders 21Immunoglobulin Light-chain Amyloidosis 18Leukemia, Myeloid, Chronic-Phase 17Dendritic Cell Sarcoma, Interdigitating 17Recurrence 15Primary Myelofibrosis 14Leukemia, Myelomonocytic, Chronic 14Congenital Abnormalities 14Blast Crisis 14Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 13Leukemia, Myeloid, Accelerated Phase 13Myelodysplastic-Myeloproliferative Diseases 12Lymphoma, T-Cell, Cutaneous 10Graft vs Host Disease 10

Interventions

Melphalan 2Filgrastim 2Fibroblast Growth Factor 7 2Cyclophosphamide 2Amifostine 2sargramostim 1Sirolimus 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Ifosfamide 1Etoposide 1Epoetin Alfa 1Deoxycytidine 1Cytarabine 1Carboplatin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Filgrastim × Plasma cell × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00004132 2013-06-26

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Radiation Injuries, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡